September 14-16 | New York, USA
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, will attend the Morgan Stanley 24th Annual Global Healthcare Conference in New York from September 14 to 16. On September 15 at 14:35 PM, he will participate in an in-person fireside chat, engaging in in-depth dialogue with global investors and industry leaders on the company's latest breakthroughs in generative AI-driven drug discovery, aging clocks, and anti-aging interventions.
As a global pioneer at the intersection of generative AI and longevity science, Dr. Zhavoronkov will represent Insilico Medicine at the Morgan Stanley Global Healthcare Conference, engaging in in-depth dialogue with leading global investors, multinational pharmaceutical companies, and innovation ecosystem leaders. He will showcase the company's latest progress in generative-AI-enabled drug discovery, aging clocks and anti-aging intervention therapies, as well as the end-to-end autonomous laboratory roadmap - further strengthening Insilico's global influence across the international capital markets and the biopharmaceutical innovation landscape.
About the Morgan Stanley Global Healthcare Conference
The Morgan Stanley Global Healthcare Conference is one of the largest and most influential healthcare investment gatherings in the world. Each year it convenes thousands of industry leaders - from multinational pharmaceutical companies and biotech innovators, to medical device and digital health pioneers, top hedge funds and long-only investors, as well as strategic consulting and regulatory bodies. Through keynote addresses, fireside chats, one-on-one investor meetings, forward-looking industry roundtables and dedicated track sessions, the conference focuses on the latest trends, frontier technologies and capital flows across global healthcare. It serves as a core venue for international investors to identify opportunities in the healthcare sector, for big pharma to engage with innovative technologies and M&A targets, and for biotech companies to showcase pipeline milestones.
September 14-16 | Riyadh, Saudi Arabia
Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to attend the Riyadh Global Medical Biotechnology Summit (RGMBS) 2026 from September 14 to 16. On September 16 (09:00-12:00), at the Sofitel Riyadh Hotel & Convention Center, Dr. Aliper will lead the Insilico team in hosting a hands-on workshop titled "Model Context Protocol (MCP)-Empowered Protein Design: Combining AI Foundation Models and Physics-Based Molecular Modelling". Participants will gain first-hand experience using MCP to connect AI foundation models, molecular simulation and databases; master the complete workflow from structure preparation to physics-based validation; learn how to score and prioritize drug candidates with AlphaFold, RDKit and OpenMM; interpret binding modes, kinetics and free-energy calculation results; and run a directed MCP workflow inside the Chemistry42 sandbox.
As Co-Founder and President of Insilico Medicine, Dr. Aliper has long been a committed explorer at the intersection of AI-driven drug discovery, frontier biomedical science and cross-disciplinary tool integration. At RGMBS 2026, he will lead the Insilico team in hosting the "MCP-Empowered Protein Design" workshop - seamlessly weaving generative AI foundation models with physics-based molecular simulation (AlphaFold, RDKit, OpenMM) and the unified Model Context Protocol. The workshop will showcase Insilico's leading role in building the Chemistry42 platform and the broader autonomous laboratory ecosystem. Attendees will also gain hands-on experience running end-to-end MCP-driven workflows - from structure preparation through physics-based validation to free-energy calculation - directly inside the Chemistry42 sandbox.
About RGMBS 2026
The Riyadh Global Medical Biotechnology Summit (RGMBS), co-initiated by the Saudi Ministry of Health, the Royal Commission for Riyadh City, and leading biomedical authorities, is one of the largest and most influential international biotechnology and medical innovation summits in the Middle East. The summit convenes top scientists, R&D leaders, clinical experts, regulators and strategic investors from biopharmaceutical, gene & cell therapy, medical device, digital health and fundamental life sciences communities worldwide. Centered on frontier biotechnology, precision medicine, AI-driven drug discovery, translational medicine, health-tech investment and biomanufacturing, the summit advances in-depth dialogue through keynote addresses, themed workshops, closed-door sessions, industry matchmaking and project roadshows - driving cross-regional, cross-disciplinary and cross-industry collaboration, and serving as a key gateway for global biopharma to engage with the Middle East market and Saudi Vision 2030's biomedical strategy.
September 17-19 | Shanghai, China
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the Bio-Shanghai Week 2026. On September 17 at 3:00 PM, during the opening ceremony's AI-Driven Innovation session, he will engage in an in-depth dialogue with Prof. Michael LEVITT - 2013 Nobel Laureate in Chemistry and Stanford University structural biology professor - on "AI-Driven Global Innovation in Therapeutic Target Discovery and Treatment Technologies".
As Co-CEO and Chief Scientific Officer of Insilico Medicine, Dr. Ren is one of the leading scientists driving AI-enabled new drug R&D and clinical translation. At Bio-Shanghai Week he will share the stage with Nobel Laureate Prof. Michael Levitt, exploring from the three dimensions of foundational science breakthroughs, industrial translation pathways and global strategic coordination, how AI is systematically reshaping the full chain of target discovery, molecular design and clinical development. He will share Insilico's practice across its generative AI platform, pipeline progress and global footprint - bringing to the stage a high-level dialogue between a leading Chinese AI-driven pharma company and a global top scientist.
About Bio-Shanghai Week
The 2026 Bio-Shanghai Week anchored by Zhangjiang Drug Valley - a national-level biopharmaceutical industry hub - is one of the largest and most internationally influential biopharmaceutical industry events in Shanghai. Each year it brings together leading global scientists, clinical experts, multinational pharmaceutical and biotech companies, innovative drug and device developers, long-only and early-stage investors, government regulators and industry service platforms. Centered on AI-driven innovation, gene & cell therapy, antibodies and ADCs, rare diseases and neuroscience, global market access for innovative drugs and devices, clinical translation and industry ecosystem, the conference advances high-level dialogue through opening forums, themed seminars, industry matchmaking, project roadshows and showcase exchanges - driving cross-border, cross-disciplinary and cross-stage collaborative innovation, and serving as a vital window into the frontier of China's biopharmaceutical industry and the broader Yangtze River Delta innovation ecosystem.
September 18 | Boston, USA
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend the Harvard IvyTech Discussion on September 18. On September 18 (10:50-12:00), he will participate in the forum titled "A Geo-Economic Shift: China's Rise as an Innovation Powerhouse in Biotech", delivering a keynote speech.
As one of the most influential entrepreneurs at the intersection of global AI-driven pharma and longevity science, Dr. Zhavoronkov has been invited to the Harvard IvyTech Discussion. He will share the stage with leading scientists, industry strategists and policy researchers from North America's top institutions to discuss the leapfrog upgrade of China's biopharmaceutical industry - from generic to first-in-class innovation - and the corresponding evolution of the global biopharma value chain and capital landscape. He will also present Insilico's overall strategic blueprint as a bridge company connecting Eastern and Western innovation ecosystems - spanning China's foundational research, the company's AI platform technology, its global R&D pipeline, and international capital and industry partnerships.
About the Harvard IvyTech Discussion
The Harvard IvyTech Discussion, co-initiated by Harvard University and other Ivy League academic institutions, focuses on frontier global technology, industrial transformation and key geo-economic topics. It is one of the most important high-level strategic dialogue platforms bridging North America's academic and industry communities. Each edition brings together leading scientists, technology executives, prominent entrepreneurs, policymakers and institutional investors from around the world - engaging in in-depth dialogue on biomedical innovation, artificial intelligence, advanced manufacturing, the energy transition, and cross-border innovation ecosystems. Through keynote addresses, themed roundtables and closed-door sessions, the discussion fosters cross-disciplinary, cross-regional and cross-industry exchange and co-creation - serving as a vital window into the evolving global innovation landscape and the increasingly close ties between Eastern and Western scientific and industrial ecosystems.
Recently, Insilico reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing, with an adjusted net profit exceeding $51 million. This milestone was driven by a series of out-licensing, co-development, and R&D collaborations with global partners, including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. As of the latest practicable date, the total contract value of transactions announced by Insilico in 2026 reached approximately $7.3 billion, pushing the cumulative contract value of its major collaborations since 2021 approximately $11 billion.
On the AI-driven R&D front, Insilico nominated nine development candidates within nine months of 2026 as of late August, setting a new company record for annual pipeline productivity and achieving eight clinical milestones across its proprietary and co-developed programs. Leading this progress is rentosertib (ISM001-055), the world's first drug candidate discovered and developed using generative AI, which has advanced to a Phase III trial evaluating for idiopathic pulmonary fibrosis (IPF).
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com